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Role of the Transforming 
Growth Factor-β in regulating 
hepatocellular carcinoma oxidative 
metabolism
Jitka Soukupova1, Andrea Malfettone1, Petra Hyroššová1,2, María-Isabel Hernández-
Alvarez3,5, Irene Peñuelas-Haro1, Esther Bertran1, Alexandra Junza4,5, Jordi Capellades4,5, 
Gianluigi Giannelli6, Oscar Yanes  4,5, Antonio Zorzano3,5,7, José Carlos Perales1,2 & Isabel 
Fabregat  1,2
Transforming Growth Factor beta (TGF-β) induces tumor cell migration and invasion. However, its role 
in inducing metabolic reprogramming is poorly understood. Here we analyzed the metabolic profile of 
hepatocellular carcinoma (HCC) cells that show differences in TGF-β expression. Oxygen consumption 
rate (OCR), extracellular acidification rate (ECAR), metabolomics and transcriptomics were performed. 
Results indicated that the switch from an epithelial to a mesenchymal/migratory phenotype in HCC 
cells is characterized by reduced mitochondrial respiration, without significant differences in glycolytic 
activity. Concomitantly, enhanced glutamine anaplerosis and biosynthetic use of TCA metabolites were 
proved through analysis of metabolite levels, as well as metabolic fluxes from U-13C6-Glucose and 
U-13C5-Glutamine. This correlated with increase in glutaminase 1 (GLS1) expression, whose inhibition 
reduced cell migration. Experiments where TGF-β function was activated with extracellular TGF-β1 
or inhibited through TGF-β receptor I silencing showed that TGF-β induces a switch from oxidative 
metabolism, coincident with a decrease in OCR and the upregulation of glutamine transporter Solute 
Carrier Family 7 Member 5 (SLC7A5) and GLS1. TGF-β also regulated the expression of key genes 
involved in the flux of glycolytic intermediates and fatty acid metabolism. Together, these results 
indicate that autocrine activation of the TGF-β pathway regulates oxidative metabolism in HCC cells.
Transforming Growth Factor beta (TGF-β) plays a dual role in liver tumorigenesis1, since it inhibits growth and 
induces apoptosis in early stages of carcinogenesis, but once cells acquire the capacity to overcome its suppressor 
effects, they respond to it undergoing epithelial-mesenchymal transition (EMT), which increases their migratory 
and invasive potential. For these reasons, targeting TGF-β has recently emerged as a promising tool in fighting 
liver cancer2. In spite of its well known effects on cell proliferation, migration and invasion, little is known about 
its capacity to induce metabolic reprogramming. Cancer cells modulate their metabolism to favor growth, sur-
vival, proliferation and long-term maintenance. The common feature of this alteration is increased glucose uptake 
and fermentation of glucose to lactate, as well as the use of glycolysis and tricarboxylic acid (TCA) cycle interme-
diates for biosynthesis and ATP production3,4.
Mortality owing to liver cancer has increased in the past years, and the latest estimates indicate that the global 
health burden of this disease will continue to grow5. Hepatocellular carcinoma (HCC) is the most frequent liver 
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tumor. It is generally diagnosed in advanced stages of the disease and, with the exception of sorafenib, no success 
has been obtained with targeted therapeutic drugs5. Likely reasons for this include inter-tumour heterogeneity, 
as well as a lack of predictive biomarkers of response. Recent evidences indicate metabolic reprogramming as 
a transcriptional hallmark of HCC6,7, which may help to identify the most aggressive lesions in early phases of 
hepatic carcinogenesis8. The principal metabolic alterations in HCC tumors would include elevated glycolysis 
and reduced TCA cycle flux9. However, the main executers of this metabolic reprogramming are not yet known. 
Proteomic analysis of a subgroup of HCC patients that presented activation of the β-catenin pathway identified 
glucose metabolism as a key metabolic pathway altered in these patients10. A previous study had indicated that 
activation of the TGF-β pathway may concur in a subgroup of patients that show alterations of the β-catenin/
Wnt pathway11. However, there is no data at present on the potential role of TGF-β in regulating glycolytic/TCA 
pathways in HCC.
Aim of this work was to perform a detailed analysis of the differences in basal metabolism amongst HCC cell 
lines that present differential expression of TGF-β, correlating with distinct epithelial/mesenchymal and migra-
tory phenotype. The potential role of TGF-β in regulating their metabolic profiles was explored in experiments 
where TGF-β function was activated with extracellular TGF-β1 or inhibited through targeting-knockdown of the 
TGF-β receptor I (TGFβRI).
Results
Aerobic glycolysis and oxidative metabolism in HCC cells that show differences in the expres-
sion of TGF-β. The metabolic status of representative HCC cell lines that presented differences in their epi-
thelial/mesenchymal phenotype and expression of TGF-β was analyzed (Fig. 1 and Supplementary Fig. S1). Cells 
expressing higher levels of TGF-β showed a mesenchymal-like morphology, coincident with loss of E-cadherin 
expression and increased levels of vimentin (Fig. 1). Increased transcript levels of N-cadherin (CDH2) and vimen-
tin (VIM) and lower levels of E-cadherin (CDH1) were observed in the more mesenchymal cells, which correlated 
with higher expression of the EMT-related transcription factors Snail (SNAI1) and Twist1 (TWIST1) and differ-
ences in their migratory capacity (Supplementary Fig. S1). High resolution respirometry (Oxygraph-2k) revealed 
that basal oxygen consumption rate (OCR) was significantly higher in epithelial PLC/PRF/5 and Huh7 cells when 
compared to the other cell lines with a mesenchymal gene expression profile, Hep3B, HLE and SNU449 (Fig. 1c). 
The amount of lactate released into the cell culture medium after 48 hours was slightly increased in the mesen-
chymal cells (Fig. 1d), although increased glucose consumption was only observed in the Hep3B cells (Fig. 1e). 
However, glucose consumption/lactate production ratio was similar in all the cell lines.
Inhibition of glycolysis with 2-deoxy-D-glucose (2-DG, a glucose analog that is not metabolized beyond the 
initial phosphorylation step) significantly compromised the proliferative capacity of mesenchymal HCC cells to 
a higher degree than in the epithelial ones (Fig. 1f and Supplementary Fig. S2). Consistently, metformin (a com-
monly used antidiabetic drug that inhibits mitochondrial Complex I of the respiratory chain) affected more the 
proliferation of epithelial cell lines characterized by higher oxidative phosphorylation (OXPHOS) activity (Fig. 1g 
and Supplementary Fig. S3).
Differences in oxidative metabolism between the epithelial PLC/PRF/5 and the mesenchymal 
SNU449 cell lines. To gain insight into the mechanisms that could explain the observed differences in oxida-
tive metabolism among the different HCC cell lines, we performed a metabolomic and transcriptomic analysis in 
the epithelial PLC/PRF/5 and the mesenchymal SNU449 cells. A full list of the metabolites and genes analyzed is 
presented in Supplementary Tables S1 and S2, respectively. Selected metabolites related to the glycolytic pathway 
that were significantly different between PLC/PRF/5 and SNU449 cells, together with key genes showing signifi-
cant changes in their expression levels, are shown in Fig. 2a,b. Glucose-6-phosphate levels were significantly lower 
in SNU449 cells (Fig. 2a), even though glucose consumption or lactate production rates were unchanged (Fig. 1e). 
An increased shunt of glucose-6-phosphate to the pentose phosphate pathway (PPP) was observed in these cells, 
as indicated by an increased expression of glucose-6-phosphate dehydrogenase (G6PD) and other PPP genes, 
such as transketolase (TKT) (Fig. 2b). Consistently, lower levels of some PPP intermediates, such as ribose-1-P or 
sedoheptulose-7-P, were measured in SNU449 cells, suggesting increased flux through this pathway. On the con-
trary, PLC/PRF/5 cells had higher phosphoglucomutase 3 (PGM3) and alpha-1,6-glucosidase (AGL) expression, 
as well as decreased glycogen phosphorylase (PYGL), indicative of enhanced conversion of glucose-6-phosphate 
to glucose-1-phosphate, and storage of glucose in the form of glycogen. Accordingly, UDP-glucose was also sig-
nificantly increased in PLC/PRF/5 cells.
Increased PPP pathway found in the SNU449 cells did not correlate with differences in proliferation (data not 
shown), but with a switch from free fatty acid (FFA) oxidation to synthesis. Indeed, expression of enzymes related 
to β-oxidation of FFA, such as carnitine palmitoyltransferase 2 (CPT2) or acyl-CoA oxidase 2 (ACOX2) was lower, 
whereas expression of genes coding enzymes involved in FFA synthesis, such as acetyl-CoA carboxylase alpha 
(ACACA), acetyl-CoA carboxylase beta (ACACB) and acyl-CoA synthetase long-chain 5 (ACSL5), were higher 
in SNU449 than in PLC/PRF/5 cells (Fig. 2c). According to this expression profile, SNU449 presented significant 
higher mRNA levels of the adipogenic transcription factor peroxisome proliferator-activated receptor gamma 
(PPARγ). In fact, FFA levels were much higher in SNU449 cells than in PLC/PRF/5 cells, which also presented 
significantly higher amounts of several phospholipids and sphingolipids (Supplementary Fig. S4). Additionally, 
SNU449 cells presented larger metabolite pools in the glycerol synthesis pathway, such as dihydroxyacetone phos-
phate, glycerol-3-phosphate and glycerol, necessary for glycerolipid synthesis (Fig. 2a). Together, these results 
suggest that the increased PPP in mesenchymal SNU449 cells may be necessary to supply NADPH for lipid 
synthesis.
Significant differences in the expression of pyruvate kinase isoenzymes were also observed. Liver isoform of 
pyruvate kinase (PKLR) was expressed in the epithelial PLC/PRF/5 cells, but was almost absent in the SNU449, 
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which predominantly expressed pyruvate kinase muscle 2 (PKM2) isotype (Fig. 2b and Supplementary Fig. S5). 
Even though pyruvate dehydrogenase A1 (PDHA1) expression was lower in PLC/PRF/5 cells, the expression 
of the component of the pyruvate dehydrogenase complex, dihydrolipoamide S-Acetyltransferase (DLAT), 
was increased in PLC/PRF/5 cells. Differential expression of lactate dehydrogenase isoenzymes was also noted: 
epithelial PLC/PRF/5 expressed lactate dehydrogenase B (LDHB), which was absent in SNU449 (Fig. 2b and 
Supplementary Fig. S5). However, despite these observations, no significant differences were observed in intra-
cellular pyruvate or lactate levels.
SNU449 cells showed increased levels of citrate, aconitate, isocitrate, α-ketoglutarate and succinate, TCA cycle 
intermediates (Fig. 3a), without relevant changes in the expression of the genes coding for the enzymes involved 
Figure 1. Glycolytic and oxidative metabolism in different HCC cell lines. (a) Immunofluorescence analysis 
of E-cadherin (green) and Vimentin (green). DAPI (blue). Scale bar represents 50 μM. (b) mRNA expression 
levels of TGF-β detected by qRT-PCR and normalized to PLC/PRF/5. Mean ± SD (n = 3). (c) OCR was analyzed 
at basal condition by high resolution respirometry (Oxygraph 2k) in DMEM supplemented with 10% FBS in 
5 × 105 cells in suspension. Results are represented as OCR pmol/seg/ml of the first 10 min of respiration after 
stabilization. (d,e) Lactate production and glucose consumption was analyzed after 48 hours of cell culture in 
DMEM supplemented with 10% FBS and normalized to cell count. (f) Cells were treated with 2-DG in a range 
of concentration (0–10 mM). Cell viability was analyzed after 72 hours by crystal violet staining and normalized 
to un-treated control. (g) Cells were treated with metformin in a range of concentration (0–10 mM). Cell 
viability was analyzed after 72 hours by crystal violet staining and normalized to un-treated control. Mean ± SD 
(n = 3, p values are explained in the table below figure).
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in this cycle. This would suggest increased TCA carbon anaplerosis in SNU449 cells. Indeed, the expression of 
glutaminase 1 (GLS1) that converts glutamine to glutamate was higher in SNU449 cells (Fig. 3a), suggesting that 
Figure 2. Metabolomic and transcriptomic analysis of PLC/PRF/5 and SNU449 cells: glucose and fatty acid 
metabolism. (a) Schematic diagram of selected metabolites of the glycolytic pathway presented as in the KEGG 
database (http://www.genome.jp/kegg/). The level of metabolites is depicted by a box plot with whiskers 
(min to max). Welch’s two-sample t-test was used to identify biochemicals that differed significantly between 
experimental groups (n = 5 for each group). *p < 0.05, **p < 0.01, ***p < 0.001. (b) Expression of selected 
genes related to the glycolytic pathway. Values < 1 indicate lower expression and values > 1 indicate higher 
expression, SNU449 as compared to PLC/PRF/5. (n = 3, p value indicated in the right column). (c) Expression 
of selected genes related to fatty acid β-oxidation and fatty acid synthesis was detected by qRT-PCR and 
normalized to PLC/PRF/5. Mean ± SD. (n at least 3). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3. Metabolomic and transcriptomic analysis of PLC/PRF/5 and SNU449 cells: differences in the TCA 
cycle and glutamine metabolism. (a) Left: Schematic diagram of the TCA cycle as presented in the KEGG 
database (http://www.genome.jp/kegg/). The level of metabolites is depicted by a box plot with whiskers 
(min to max). Welch’s two-sample t-test was used to identify metabolites that differed significantly between 
experimental groups (n = 5 for each group). *p < 0.05, **p < 0.01, ***p < 0.001. Right: Expression of FH and 
selected genes related to the glutamine metabolism pathway. Values < 1 indicate lower expression and values > 1 
indicate higher expression, SNU449 as compared to PLC/PRF/5. (n = 3, p value indicated in the right column). 
(b) Metabolites from the glutamine/glutamate pathway presented in fold comparing SNU449 to PLC/PRF/5. 
Welch’s two-sample t-test was used to identify metabolites that differed significantly between experimental 
groups (n = 5 for each group, p value indicated in the right column). (c) PLC/PRF/5 cells and SNU449 were 
cultivated in DMEM medium (25 mM glucose) without glutamine supplemented with 10% FBS. Cell viability 
was analyzed after 24, 48 and 72 hours by crystal violet staining and normalized to control (2 mM glutamine). 
Mean ± SD (n = 3), **p < 0.01, ***p < 0.001.
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glutamine anaplerosis might be responsible for increased TCA intermediates pool size. Analysis of the expres-
sion of glutamine synthase (GS), responsible for production of endogenous glutamine, revealed that SNU449 
cells showed significantly lower mRNA levels than PLC/PRF/5 cells (Fig. 3a), suggesting that SNU449 might 
be more dependent on exogenous glutamine due to the lack of GS for endogenous glutamine production, In 
contrast, the expression of the amino acid transporter Solute Carrier Family 7 Member 5 (SLC7A5), a mem-
ber of the Sodium-Independent Neutral Amino Acid Transporter LAT 1 complex that exchanges glutamine by 
other essential amino acids (EAA), was increased in SNU449. These results indicate that the main source of 
glutamine for anaplerosis in SNU449 cells is extracellular. Metabolites from the glutamine metabolism pathway, 
such as N-acetylglutamine, 4-hydroxyglutamate and pyroglutamine, were found to be decreased in SNU449 cells 
(Fig. 3b). Accordingly, these cells presented significantly reduced cell viability after 48 and 72 hours of glutamine 
depletion compared to PLC/PRF/5 (Fig. 3c). Furthermore, glutamine anaplerosis favors the migratory phenotype 
of the SNU449 cells, since treating them with a selective inhibitor of GLS1 (BPTES, 10 μM, 12 hours treatment, 
which at this time it does not induce changes in cell viability), significantly decreased cell migration, as assessed 
by the real time migration assay (xCELLigence System) (Supplementary Fig. S6).
To further elucidate the dynamics of the TCA cycle and glutamine anaplerosis in PLC/PRF/5 versus SNU449 
cells, we performed isotopologue enrichment analysis using universally labeled glutamine (U-13C5-Glutamine) 
and glucose (U-13C6-Glucose). Stable isotope labeling of key intermediates of the TCA cycle and glycolysis were 
quantified using mass spectrometry (MS). As shown in Fig. 4a, isotope enrichment analysis of glutamate, malate 
and citrate provides strong evidence for increased anaplerosis of glutamine in SNU449 cells. Fully labeled glu-
tamate (m + 5) and malate (m + 4) distribution significantly increased in SNU449 cells, suggesting increased 
labeled glutamine flux into the TCA cycle. This was further confirmed by increased enrichment in citrate spe-
cies (m + 4) corresponding to the direct oxaloacetate flux from glutamine. Consistently, when cells were labeled 
with U-13C6-Glucose, unlabeled species (m + 0) were significantly higher in SNU449 cells, indicating lower 
contribution of glucose carbons into the TCA cycle intermediate pool (Fig. 4b). Metabolic flux analysis using 
U-13C6-Glucose confirmed reduced pyruvate enrichment (m + 3), while maintaining identical glucose to lactate 
flux in PLC/PRF/5 versus SNU449 (Fig. 4c). Further analysis of the contribution of the pyruvate carboxylase (PC) 
Figure 4. 13C isotopomer distribution from fully labeled glutamine/glucose. (a) PLC/PRF/5 and SNU449 
cells were exposed to 4 mM fully labeled glutamine (U-13C5-Glutamine) in a medium containing 25 mM 
glucose and 10% dialyzed FBS. (b–d) PLC/PRF/5 and SNU449 cells were exposed to 25 mM fully labeled 
glucose (U-13C6-Glucose) in a medium containing 4 mM glutamine and 10% dialyzed FBS. As 13C from 
glutamine/glucose is distributed among various metabolites, their mass increases proportionally to the number 
of incorporated carbons. This increase in mass was detected by GC-MS. Isotope distribution in metabolites 
is marked as m + x, where the m stands for natural mass of the metabolite and the x indicates number of 
incorporated 13C carbons. Mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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and PDH fluxes into citrate (m + 3 and m + 5 versus m + 2, respectively) demonstrated that PLC/PRF/5 cells have 
a higher PC directed entry of pyruvate into the TCA cycle (higher enrichment in m + 3 and m + 5 citrate spe-
cies), whereas PDH flux was unaffected (Fig. 4c,d), suggesting that the accumulation of fully labeled pyruvate in 
SNU449 was due to reduced entry into the TCA cycle, probably as glutamine anaplerosis was substantially higher. 
TCA cycling, identified by the distribution of m + 2 species (2nd turn of the cycle), was not different between both 
cell lines (data not shown), suggesting that increased glutamine carbon flux in SNU449 was directed towards 
biosynthetic processes.
In summary, these results indicate that epithelial and mesenchymal HCC cell lines differ in their glucose and 
glutamine utilization pathways, correlating with differential expression of key regulatory genes. Results also indi-
cate that the TCA cycle supports a more biosynthetic role in the mesenchymal cell line, coincident with increased 
glutamine anaplerosis, which would be essential for the cell migratory phenotype.
Role of TGF-β on the metabolic adaptations of HCC cells. We next wondered whether the observed 
differences in metabolism between these epithelial/mesenchymal cell lines might be attributed to the TGF-β 
produced by those cells (see Fig. 1b). Therefore, we chronically treated an epithelial PLC/PRF/5 cell line with 
TGF-β (2 ng/ml) for two weeks (gain of function). TGF-β treated PLC/PRF/5 (TβT-PLC) cells presented 
up-regulation of characteristic mesenchymal genes, such as CDH2, VIM or TWIST1, although the expression of 
CDH1 was maintained (Supplementary Fig. S7a,b). Importantly, in spite of decreased cell proliferation, due to 
the inhibitory effects of TGF-β, TβT-PLC cells showed enhanced migratory capacity (Supplementary Fig. S7c,d). 
In parallel, TGFβRI was stably downregulated in the mesenchymal HCC cell line, SNU449 (loss of function: 
SNU449sh-control cells transfected with unspecific shRNA; SNU449shTβRI- silenced cells transfected with 
specific shRNA). TGFβRI silencing did not provoke a full mesenchymal-epithelial transition (MET), although 
we could observe decreased expression of key EMT-related transcription factors, such as SNAI1 and TWIST1 
and the reorganization of F-actin in pericellular area. Furthermore, SNU449shTβRI cells presented significantly 
decreased cell migration capacity, with no changes in cell proliferation (Supplementary Fig. S8).
To better explore mitochondrial physiology, we measured oxygen consumption rates (OCR) during sequen-
tial treatment with compounds that modulate mitochondrial activity using a Seahorse apparatus (more details 
in the Methods section). PLC/PRF/5 cells showed high basal mitochondrial oxygen consumption that was 50% 
coupled to ATP production. Chronic activation of these cells with TGF-β induced a significant decrease in basal, 
ATP-linked and maximal OCR (FCCP treated) (Fig. 5a). Control PLC cells were able to increase OCR after 
FCCP treatment (maximal OCR), indicating spare respiratory capacity. However, TβT-PLC cells did not show a 
significant increase in OCR after FCCP addition. Mesenchymal SNU449 cells showed lower basal OCR (similar 
in value to the one observed in TβT-PLC cells) and they were not able to increase OCR after addition of FCCP. 
Knockdown of TGFβRI in SNU449 cells led to a significant increase in ATP-linked and maximal OCR, without 
affecting basal OCR (Fig. 5b). No differences were observed in basal extracellular acidification rate (ECAR) or 
lactate production at 48 hours among the cell lines (Supplementary Fig. S9), suggesting that differences in mito-
chondrial respiration do not correlate with opposing changes in glycolytic capacity. This was confirmed when we 
measured ECAR during sequential treatment with compounds that modulate glycolytic activity (Fig. 5c,d). In 
TβT-PLC cells we observed a tendency to lower ECAR, and no changes were observed in glycolytic capacity or in 
glycolytic reserve. In SNU449shTβRI cells, no differences in ECAR were observed when compared to SNU449sh- 
control cells.
Altogether, these results indicate that the TGF-β pathway regulates mitochondrial respiratory capacity in HCC 
cells.
Metabolomics and transcriptomics analyses suggest a role for TGF-β in regulating key met-
abolic pathways in HCC cells. Metabolomic analysis of PLC versus TβT-PLC and SNU449sh- versus 
SNU449shTβRI cells revealed a number of metabolites significantly altered (Supplementary Fig. S10a). Pathway 
set enrichment analysis displayed the number of experimentally regulated compounds relative to all detected 
compounds in a pathway (Supplementary Fig. S10b). The unsupervised hierarchical clustering was performed 
using Euclidean distance and showing differences between the respective groups (Supplementary Fig. S10c).
We used a p-value of 0.05 as a cut-off to analyze consistent changes induced by TGF-β (with increased levels in 
TβT-PLC cells and decreased levels in SNU449shTβRI cells and vice versa: Supplementary Table S3). Interestingly, 
levels of amino acids were generally decreased in TGF-β exposed cells (TβT-PLC versus PLC and SNU449sh- 
versus SNU449shTβRI), namely threonine, N-acetylalanine, N-acetylasparagine, glutamine, N-acetylglutamine, 
N-acetyl-aspartyl-glutamate (NAAG), N6, N6, N6-trimethyllysine and methionine sulfone. Importantly, 
the observed changes in downstream glutamate metabolites (Fig. 6a,b) were accompanied by changes in gene 
expression (Fig. 6c). GLS1 expression was increased in TβT-PLC cells and decreased in SNU449shTβRI cells. 
Additionally, SNU449shTβRI showed reduced expression of glutamine transporter SLC7A5. These results 
strongly suggest a role for TGF-β in regulating glutamine metabolism in HCC cells. It is worth noting that acti-
vation of the TGF-β pathway (TβT-PLC and SNU449sh-) correlated with significantly higher levels of succinate, 
suggesting an increased entry of glutamine to the TCA cycle (Fig. 6b).
Moreover, additional changes in glucose metabolism might be under the control of TGF-β. The most inter-
esting finding after chronic activation of PLC/PRF/5 cells with TGF-β was the switch in the expression of LDHA 
and LDHB (Fig. 7a), reminiscent of the expression pattern observed in SNU449 cells (Fig. 2), although no dif-
ferences in lactate levels were detected. Inhibition of the TGF-β pathway in SNU449shTβRI cells correlated 
with reduced expression of PPP-related genes, such as G6PD, hexose-6-phosphate dehydrogenase (H6PD) and 
6-phosphogluconolactonase (PGLS), which indicated a role for the autocrine TGF-β pathway in pushing glucose 
through the PPP. Furthermore, in SNU449shTβRI cells, decreased levels of sphingolipids and phospholipids were 
detected (Supplementary Fig. S11 a + b) together with decreased expression of genes that play a regulatory role 
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Figure 5. Seahorse analysis of OXPHOS and glycolysis in HCC cells. Role of the TGF-β pathway. (a,b) OCR 
normalized to protein content in PLC, TβT-PLC (a) and SNU449sh-, SNU449shTβRI cells (b) incubated 
30 minutes prior experiment in XF assay medium supplemented with 5 mM glucose and 2 mM glutamine 
and consecutively injected with oligomycin (1 μM), FCCP (1.5 μM), antimycin (1 μM) and rotenone (1 μM). 
Continuous OCR values (pmoles/min/µg protein) are shown. Mitochondrial functions were analysed as 
explained in Supplementary materials and methods. The % of ATP-linked OCR was calculated as ATP-linked 
OCR/basal OCR. Mean ± SEM (n at least 6 from three independent experiments). *p < 0.05, **p < 0.01, 
***p < 0.001. (c,d) ECAR in PLC, TβT-PLC (c) and SNU449sh-, SNU449shTβRI cells (d) incubated 
30 minutes prior experiment in XF assay medium supplemented with 2 mM glutamine and consecutively 
injected with glucose (10 mM), oligomycin (1 μM) and deoxyglucose (50 mM). Mean ± SEM (n at least 9 from 
three independent experiments). Continuous ECAR values (mpH/min/µg protein) are shown. Glycolytic 
functions were analysed as explained in Supplementary materials and methods. Mean ± SEM (n = 9 from three 
independent experiments). Glucose consumption (mg/105 cells) was measured after 48 hours of culture in 
DMEM supplemented with 10% FBS and normalized to cell number. Mean ± SD (n = 3).
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in FFA synthesis, such as ACSL5 and PPARγ (Supplementary Fig. S11c). These results together indicate that the 
autocrine TGF-β pathway in SNU449 cells regulates NADPH synthesis, through an increase of the oxidative PPP 
pathway, and lipid synthesis.
Pyruvate levels presented a tendency to decrease (86% of control, p = 0.07), which could be due to an increase 
in pyruvate to acetylCoA conversion. Pyruvate dehydrogenase kinase 2 (PDK2) and pyruvate dehydrogenase 
kinase 4 (PDK4) were significantly decreased, resulting in increased pyruvate dehydrogenase activity. Indeed, the 
level of acetylCoA was increased in the SNU449shTβRI cells (Fig. 7b). Interestingly, UDP-glucose levels signifi-
cantly increased after TGFβRI silencing.
All together, these results indicate that autocrine activation of the TGF-β pathway may be responsible for 
many of the differences observed in the pattern of metabolites and gene expression found in SNU449 when com-
pared to the PLC/PRF/5 cells (Fig. 2). However, in the case of PKs, although a trend towards an increase in the 
expression of PKLR and a decrease in PKM2 expression was observed in the SNU449shTβRI, changes were not 
significant and the expression of these enzymes did not change in the TβT-PLC cells (Fig. 7c). Indeed, changes in 
the PKs enzyme expression were not under the control of the TGF-β pathway.
Discussion
Tumor cells adapt their metabolic pathways to support oncogenic growth under adverse situations and to take 
full advantage of their energy reserves in new functions, such as cell migration and invasion3,4. HCC is a highly 
heterogeneous cancer, represented by strong differences among the patients both in phenotype and in molecular 
profiles5. In previous studies from our group we postulated that differences in the expression of TGF-β cor-
relate with differences in the expression of mesenchymal genes both in HCC cell lines and in HCC patients12. 
Furthermore, autocrine expression of TGF-β is responsible for differences in the stem and migratory phenotype 
of HCC cells13,14. Although several clues suggest that metabolic reprogramming may be a transcriptional hallmark 
in the process to liver carcinogenesis6–8,15, there is still no explanation for the heterogeneity of metabolic profiles 
found among the different HCC phenotypes, nor the metabolic adaptations of HCC cells to support their migra-
tion and invasion.
Our study focuses on this issue, exploring the differences of oxidative metabolism among different HCC cell 
lines that present differential epithelial/mesenchymal characteristics, as well as different autocrine production of 
TGF-β. Results indicate that the switch from an epithelial to a mesenchymal/migratory phenotype in HCC cells is 
characterized by reduced mitochondrial respiration and enhanced glutamine anaplerosis, proved through analy-
sis of metabolite levels, as well as metabolic fluxes from U-13C6-Glucose and U-13C5-Glutamine, which suggest 
an enhanced biosynthetic use of TCA metabolites. Interestingly, these changes occur in the absence of significant 
Figure 6. Role of the TGF-β pathway on glutamine metabolism in HCC cells. TβT-PLC cells were compared 
to PLC cells. SNU449sh- cells were compared to SNU449shTβRI cells. (a) Metabolites from the glutamine/
glutamate metabolism pathway presented in fold. Welch’s two-sample t-test was used to identify metabolites 
that differed significantly between experimental groups (n = 5 for each group, p value indicated in the right 
column). (b) The level of respective metabolites that changed significantly in both conditions is depicted by a 
box plot with whiskers (min to max). Mean ± SD (n = 5 for each group); *p < 0.05, **p < 0.01, ***p < 0.001. 
(c) Expression of selected genes related to the glutamine metabolism. Values < 1 indicates lower expression and 
values > 1 indicates higher expression, as compared to respective controls (n = 3, p value indicated in the right 
column).
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Figure 7. Role of TGF-β in the regulation of glucose metabolism. (a) Left: Lactate levels between PLC and 
TβT-PLC are depicted by a box plot with whiskers (min to max). Welch’s two-sample t-test was used to identify 
biochemicals that differed significantly between experimental groups (n = 5 for each group). Right: Expression 
of LDHA and LDHB. Values < 1 indicate lower expression and values > 1 indicate higher expression, TβT-PLC 
versus PLC (n = 3, p value indicated in the right column). (b) Left: Schematic diagram of selected metabolites of 
the glycolytic pathway presented as in the KEGG database (http://www.genome.jp/kegg/). The level of respective 
metabolites between SNU449sh- and SNU449shTβRI is depicted by a box plot with whiskers (min to max). 
Welch’s two-sample t-test was used to identify biochemicals that differed significantly between experimental 
groups (n = 5 for each group). *p < 0.05 Right: Expression of selected genes related to the specific parts of the 
pathway. Values < 1 indicate lower expression and values > 1 indicate higher expression, SNU449sh- versus 
SNU449shTβRI (n = 3, p value indicated in the right column). (c) Expression of PKLR and PKM2 in TβT-PLC 
versus PLC and in SNU449sh- versus SNU449shTβRI. Values < 1 indicate lower expression and values > 1 
indicate higher expression. (n = 3, p value indicated in the right column).
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differences in glycolytic activity. Glycolysis was similar in a panel of HCC cells and metabolic flux analysis using 
U-13C6-Glucose revealed identical glucose to lactate flux in the epithelial PLC/PRF/5 versus the mesenchymal 
SNU449. Pyruvate carboxylase flux would explain the increased OCR in PLC/PRF/5 cells.
Gain of TGF-β function experiments demonstrate that when an epithelial (low TGF-β production) cell line 
is chronically incubated with TGF-β, significant decreases in OCR are observed at all levels: basal, ATP-linked 
and maximal. By contrary, targeting knock-down the TGFβRI in a mesenchymal cell line provokes an increase in 
maximal OCR, as well as in the percentage of OCR dedicated to ATP synthesis. In both cases, glycolytic activity 
does not suffer relevant changes. It is noteworthy that both gain and loss of function experiments consistently 
reflect a role for TGF-β in regulating glutamine metabolism. Indeed, differences observed between epithelial 
and mesenchymal cells on glutamate/glutamine metabolites are mimicked by TGF-β treatment of the epithe-
lial cells and are reversed by silencing TGFβRI in the mesenchymal cells. The main target of TGF-β to mediate 
these changes could be GLS1 and the glutamine transporter SLC7A5. Glutamine is the major systemic carrier 
of nitrogen. It is also a key nutrient for numerous intracellular processes, including oxidative metabolism and 
ATP generation, but also biosynthesis of proteins, lipids and nucleic acids16. The demand of this amino acid can 
become so great during tumorigenesis that many cancer cells are glutamine addicted16. Glutaminolysis starts 
with the conversion of glutamine to glutamate, catalyzed by the glutaminases (GLS1 and GLS2) in the mitochon-
dria. Previous studies have shown that GLSs are expressed in a wide variety of tumors, correlating with tumor 
growth, however its regulation in cancer cells is not well understood17. Worth mentioning that none of the HCC 
cells used in this study express GLS2, which would be an advantage to the tumor cells, since it has been recently 
proposed that GLS2 exhibits a tumor suppressive function18. In fact, a glutaminolysis independent function of 
GLS2 inhibits migration and invasion of HCC cells by repressing EMT19. A metabolic switch from GLS2 to GLS1 
was observed in a series of tissues representing progressive pathologic states mimicking HCC oncogenic trans-
formation; moreover high expression of GLS1 and low expression of GLS2 in HCC was found to correlate with 
survival in HCC patients20. Here we show that TGF-β upregulates GLS1 in liver tumor cells. Through increasing 
glutamine transport and GLS1 expression, TGF-β would be favoring increased glutamate content, which would 
push carbons through the TCA cycle. In agreement with this, succinate levels are increased under all the con-
ditions where the TGF-β pathway is activated. Since the ATP-linked OCR decreases in cells where the TGF-β 
pathway is more active, TCA may support other purposes, probably biosynthetic pathways. This metabolic switch 
would offer advantages to the migratory cells, as confirmed by our results revealing a significant decrease in the 
migratory capacity of SNU449 cells when GLS1 activity is inhibited, similar to the decrease observed when the 
expression of the TGFβRI is attenuated with shRNA. It has been recently proposed that mitochondrial catabolic 
capacity may be a limiting constraint preventing complete substrate catabolism in high uptake metabolism in 
cancer cells, whereas glutamine addiction may provide resistance to metabolic stress through excess redox and 
energy production21.
A comparison of the metabolite and gene expression profile between the more epithelial and the more mes-
enchymal HCC cells reflects clear differences in the utilization of glycolytic metabolites. Indeed, epithelial cells, 
such as PLC/PRF/5, are using glucose to store it in glycogen, whereas mesenchymal/migratory cells, such as 
SNU449, direct it towards the PPP cycle, correlating with higher glycerol metabolism and lipid biosynthesis. 
G6PD and TKT transcript levels, involved in the PPP cycle, are significantly higher in the mesenchymal/migra-
tory cells when compared to the epithelial ones. Furthermore, genes related to FFA oxidation show lower expres-
sion, concomitant with increased expression of some genes related to FFA biosynthesis. All these data suggest 
that the mesenchymal/migratory phenotype would require higher lipogenesis. In this line of evidence, it has 
been recently suggested that treatment of human liver cancer cell lines with FFAs exacerbate the EMT pheno-
type, whereas chemical inhibition of CD36 mitigated these effects22. In human HCC samples, increased G6PD 
expression correlates with grading, metastasis and poor prognosis8 and decreased G6PD expression results in 
inhibition of hepatoma cell migration and invasion23. Our results indicate that regulation of the G6PD and H6PD 
expression is dependent on TGF-β, since attenuation of the pathway with TGFβR1 shRNA significantly decreases 
their transcript levels. Furthermore, storage of glycogen might be increased after TGFβRI silencing, as reflected 
by the increase in UDP-glucose levels. Finally, TGF-β also regulates genes related to lipid synthesis, such as ACSL5 
and PPARγ, and altogether contributes to the observed decrease in lipid content in SNU449 cells after TGFβRI 
silencing.
Another relevant finding of our study is the role that TGF-β would play in switching the expression of the 
LDH genes, favoring LDHA expression. Lactate dehydrogenases catalyze the inter-conversion of pyruvate to lac-
tate and NADH to NAD+. Different tissues in the body have different metabolic rates, energy requirements and 
functions, which are often reflected by the LDHA/LDHB ratio. LDHA is known as the M subunit and, although 
predominantly found in the heart, it plays many roles both in non-neoplastic and cancer cells24. LDHA is ele-
vated in many types of cancers and has been linked to tumor growth, maintenance, and invasion; therefore, 
its inhibition may restrict the energy supply in tumors and thereby reduce the metastatic and invasive poten-
tial of cancer cells25. Supporting this idea, knockdown of LDHA induces apoptosis in HCC cells and suppresses 
tumor growth and metastasis in a xenograft mouse model26. Furthermore, low expression of LDHB correlates 
with unfavorable survival in HCC27. Little is known on the factors that regulate the increase in LDHA and/or 
decrease in LDHB expression in HCC and here we propose that TGF-β would be one of these factors. There are 
multiple evidences that support this hypothesis: i) LDHA transcript levels are higher in mesenchymal HCC cells, 
which barely express LDHB, correlating with TGF-β expression; ii) a significant switch in the LDHA/LDHB ratio 
is observed after chronic stimulation of HCC cells with TGF-β. Silencing TGFβRI in mesenchymal HCC cells 
induces a modest, not statistically significant, increase in LDHB expression without changing LDHA transcript 
levels, which would indicate that in advanced stages other factors may contribute to maintain the expression of 
this gene. Further study is required to better understand the relevance of this LDHA/LDHB switch in HCC cells, 
since our result indicate that it does not correlate with significant differences in lactate levels.
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Our study also identifies some differences in the metabolic profile between epithelial and mesenchymal/
migratory HCC cells that would not be related to differential expression of TGF-β in these cells. PKLR expression 
was absent in the mesenchymal SNU449 cells, which predominantly expressed PKM2, which is the more abun-
dant form of PK in cancer cells, conferring substantial benefits on the rapidly growing tumorigenic cells. In con-
trast, forced expression of the PKM1 isoform has been associated with reduced tumor cell proliferation28. It has 
been recently suggested that switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming 
in hepatocarcinogenesis29. Furthermore, PKM2 expression indicates poor prognosis in HCC and would medi-
ate metastasis30. Our results do not support a clear role for TGF-β in up-regulating PKM2 expression. Indeed, 
extracellular TGF-β does not produce changes in pyruvate levels and does not increase PKM2 expression in the 
epithelial cell line. Furthermore, although silencing TGFβRI in the mesenchymal cell line produces a decrease in 
the pyruvate and in PKM2 transcript levels, changes are not statistically significant.
In summary, our study clearly supports that many of the differences observed in the oxidative metabolism 
among epithelial and mesenchymal HCC cells may be explained by differences in the degree of activation of the 
TGF-β pathway. We propose a new protumorigenic role for TGF-β in HCC cells: through decreasing mitochon-
drial respiration and enhancing glutamine anaplerosis and PPP cycle, TGF-β switches cell metabolism to a more 
biosynthetic profile, which would favor the migratory and invasive phenotype.
Materials and Methods
Cell culture. PLC/PRF/5, Hep3B and SNU449 cells were obtained from the European Collection of Cell 
Cultures (ECACC). Huh7 and HLE cells were from the Japanese Collection of Research Bioresources Cell Bank 
(JCRB Cell Bank). Cell lines were never used in the laboratory for longer than four months after receipt or resus-
citation. Characteristics of all the cell lines are presented in Supplementary Table S5. All cells were maintained 
in DMEM media (Lonza, Basel, Switzerland) supplemented with 10% FBS (Sera Laboratories International 
Ltd, West Sussex, UK), Penicillin (100 U/ml), Streptomycin (100 μg/ml) and Amphotericin (2.5 μg/ml) and 
L-glutamine (2 mM). They were maintained in a humidified atmosphere at 37 °C, 5% CO2. For chronical TGF-β 
treatment, human recombinant TGF–β1 (Calbiochem, La Jolla, USA) was used at 2 ng/ml in a medium and 
replaced every 48 hours. Cells were observed under an Olympus 70iX microscope. Methods for immunofluores-
cence, western blot analysis and flow cytometry analysis are included in Supplementary materials and methods.
Targeted know-down assays. For stable transfection of short hairpin RNA (shRNA), cells at 50–60% 
confluence were transfected with MAtra-A reagent (IBA GmbH, Goettingen, Germany) at a dilution of 1:600 in 
complete media, according to the manufacturer’s recommendation, using 2 µg/ml of shRNA plasmid, as previ-
ously described12. Additional information in Supplementary materials and methods.
Analysis of gene expression. A total RNA was extracted using E.Z.N.A Total RNA kit I (OMEGA Biotek, 
Nocross, USA) according to the manufacturer’s protocol. Reverse transcription (RT) was done using the High 
Capacity Reverse Transcriptase kit (Applied Biosystems, Foster City, USA), and 1 μg of total RNA from each 
sample for complementary DNA synthesis. For qRT-PCR, expression levels were determined in duplicate 
in a LightCycler 480 Real-time PCR system, using the LightCycler 480 SYBR Green I Master (Roche, Basel, 
Switzerland) and normalized to housekeeping gene L32. The list of primers used in the study in Supplementary 
materials and methods. The expression of glutamine synthase (GS) was analyzed using a TaqMan gene expression 
assay (Hs00365928_g1) according to manufacturer´s instructions.
RT profiler array. A total RNA was extracted using E.Z.N.A Total RNA kit I (OMEGA Biotek, Nocross, 
USA) according to the manufacturer’s protocol and reverse transcribed to cDNA using Reverse transcriptase First 
strand kit (Qiagen, Hilden, Germany). The human glucose metabolism RT2 Profiler PCR Array (Qiagen, Hilden, 
Germany) was used to screen 84 genes in a LightCycler 480 Real-time PCR system using the LightCycler 480 
SYBR Green I Master (Roche, Basel, Switzerland). For data analysis, fold-changes in each gene expression were 
calculated using the ΔΔCt method, after normalization to housekeeping gene (RPLP0) using a data analysis RT2 
profiler platform (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
Migration assay. Real-time assay of cell motility was examined through the xCELLigence System (ACEA 
Biosciences, San Diego, USA) as previously described12. 4 × 104 cells/well were seeded onto the top chamber of a 
CIM plate®, which was coated with a collagen IV solution (Sigma-Aldrich) and placed onto the Real-Time Cell 
Analyzer (RTCA) station (ACEA Biosciences, San Diego, USA). Continuous values were represented as Cell 
Index (CI), a dimensionless parameter, which reflects a relative change in measured electrical impedance, and 
quantified as a slope (h−1) of the first 8 hours of cell migration.
Metabolic profiling. Cell samples (100 μl of cell pellet, five replicates for each group) were submitted for 
metabolic profiling to Metabolon Inc. In brief, samples were extracted in methanol and the resulting extract was 
divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with pos-
itive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, 
one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. 
Proprietary software was used to match ions to an in-house library of standards for metabolite identification and 
quantification. Following normalization to Bradford protein concentration, log transformation and imputation 
of missing values, if any, with the minimum observed value for each compound, a Welch´s two-sample-t-test was 
used to identify molecules that differed significantly between experimental groups.
Metabolic flux assay. Cells have been seeded in 10 cm Petri dish. When confluent, cells were washed 3 
times with PBS and treatment medium was added. For glutamine labeling DMEM medium with 25 mM glucose 
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containing 10% dialyzed FBS and 4 mM fully labeled glutamine (Cambridge Isotope Laboratories Inc., product ref-
erence CLM-1822-H-PK) was used. For glucose labeling DMEM medium without glucose containing 10% dialyzed 
FBS, 4 mM glutamine and 25 mM fully labeled glucose (Cambridge Isotope Laboratories Inc., product reference 
CML-1396-PK) was used. Cells were incubated for 6 hours at 37 °C and 5% CO2. After 6 hours, cells were trypsinized 
and washed 3 times with cold PBS. Cell pellets were frozen and stored at −80 °C until metabolites extraction.
Metabolites were extracted by adding 300 µl of cold methanol/water (8:1, v:v). Samples were vortexed for 
30 seconds and immersed in liquid N2 to disrupt cell membranes followed by 10 seconds of bath-sonication. These 
two steps were repeated 3 times. Cell lysates were incubated for 20 minutes in ice before centrifugation (5000 g, 
15 minutes at 4 °C). 10 µl of 13C-glycerol (150 ppm) was added to the supernatant as internal standard. Next, 
250 µl of each sample were dried under a stream of N2 gas. Lyophilized polar extracts were incubated with 50 µL 
methoxyamine in pyridine (40 µg/µl) for 45 minutes at 60 °C. To increase volatility of the compounds, we silylated 
the samples using 25 µl N-methyl-N-trimethylsilyltrifluoroacetamide with 1% trimethylchlorosilane (Thermo 
Fisher Scientific) for 30 minutes at 60 °C. A 7890 A GC system coupled to a 7000 QqQ mass spectrometer (Agilent 
Technologies, Palo Alto, CA.) was used for isotopologue determination. Derivatized samples were injected (1 µl) 
in the gas chromatograph system with a split inlet equipped with a J&W Scientific DB5−MS+DG stationary 
phase column (30 mm × 0.25 mm i.d., 0.1 µm film, Agilent Technologies). Helium was used as a carrier gas at 
a flow rate of 1 ml/minute in constant flow mode. The injector split ratio was adjusted to 1:5 and oven tempera-
ture was programmed at 70 °C for 1 minute and increased at 10 °C/minute to 325 °C. The ionization performed 
was positive chemical ionization (CI) with isobutene as reagent gas. Mass spectral data on the 7000 QqQ were 
acquired in scan mode monitoring selected ion clusters of the different metabolites.
High-resolution respirometry. To determine OCR, 5 × 105 cells were resuspended in 1 ml fresh warm 
medium (DMEM supplemented with 10% FBS and 2 mM glutamine) and placed into Oxygraph chamber 
(Oxygraph-2k, Oroboros, Innsbruck, Austria) pre-equilibrated with 21% oxygen, equipped with a thermostat 
control (stable 37 °C), a micro stirring device and a oxygen electrode disk. After stabilization of the instrument, 
cells were left to respire for 10 minutes to monitor the oxygen consumption. The experiment was repeated at least 
three times.
Seahorse analysis. The Seahorse analyzer XF24 (Agilent, Santa Clara, USA) was used to continuously mon-
itor OCR and ECAR. Two days prior to the experiment, 20 000 cells/ well were seeded in a XF24 cell culture 
plate in DMEM media supplemented with 10% FBS, 25 mM glucose, 2 mM glutamine and cultivated at 37 °C in 
humidified atmosphere and 5% CO2. One day prior to the experiment, 1 ml of XF calibrator was added to each 
well of the XF cartridge and incubated overnight at 37 °C in humidified atmosphere and 0% CO2. 30 minutes 
prior to the experiment, cells were washed with PBS and 625 μl of respective XF assay medium was added per 
well and incubated for 30 minutes at 37 °C in humidified atmosphere and 0% CO2. For the XF Cell Mito Stress 
analysis, XF assay medium was supplemented with 5 mM glucose and 2 mM glutamine. For XF Glycolysis stress 
kit XF assay medium was supplemented with 2 mM glutamine. After 15 min equilibration time, OCR and ECAR 
were accessed every 8:30 minutes (after 3 minutes mixing, 2 minutes wait, 3:30 minutes measure), always 4 times 
after the addition of the respective compounds. The different compounds were added to the injection ports of 
the XF cartridge in 10x of final concentration and were diluted prior the experiment in XF assay medium. After 
the Seahorse experiment, all the cells were recovered, firstly the medium with any floating cells was centrifuged, 
and remaining cells were lysed using a lysis buffer (0.1 N NaOH, 0.1% SDS). Protein concentration was deter-
mined using Pierce BCA protein assay kit (Thermo Fisher Scientific) for normalization. Additional information 
in Supplementary materials and methods.
Cell proliferation assay. Cells were seeded in a 24-well plate (10 000 cells/well) in 500 μl of DMEM (Lonza 
BE12-604) supplemented with 10% FBS, 2 mM glutamine and penicillin/streptomycin (Gibco). After 24 hours, 
the media was replaced with media containing respective compounds. At specific time points (indicated in figure 
legends), cells were washed with PBS and stained with crystal violet (0.2% crystal violet in 2% ethanol solution) 
for 30 minutes and later washed with distilled water and dissolved in 10% SDS on a shaker for 30 min. The absorb-
ance was analyzed on a plate reader at 560 nm.
Inhibitors used. 2-DG (Sigma Aldrich. D8375, 2 M stock solution in distilled water, working concentration 
0–10 mM). Metformin (1,1 dimethylbiguanide hydrochloride, Sigma Aldrich D150959). 1 M stock solution in 
distilled water, working concentration 0–10 mM). BPTES (Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl 
sulfide, Sigma Aldrich SML0601, stock solution in DMSO, working concentration 10 μM).
Glutamine deprivation. Cell were seeded in a 24-well plate (10–15 000 cells/well) in 500 μl of full DMEM 
supplemented with 10% FBS, 2 mM glutamine and penicillin/streptomycin (Gibco). After 24 hours, the cells were 
washed twice with glutamine-free DMEM (Lonza, 12–614) and incubated for up to 72 hours in glutamine-free 
medium with penicillin/streptomycin and 10% FBS. As a control, glutamine was added to the glutamine-free 
DMEM (2 mM).
Lactate production and glucose consumption assays. Cells were seeded in full media in a 6-well plate 
(8 × 104 cells in 2 ml) in triplicates. Media was replaced after 24 hours. After 48 hours the media was collected for 
analysis of L-lactate and glucose and cells were counted for normalization. The concentration of L-lactate was deter-
mined using an enzymatic reaction based on the oxidation of L-lactate to pyruvate as previously described31. The 
concentration of glucose was determined using a glucose oxidase and peroxidase method, PGO Enzymes (Sigma 
Aldrich) according to manufacturer’s instructions. Additional information in Supplementary materials and methods.
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Statistical analyses. All data represent at least three experiments and are expressed as the mean ± standard 
deviation (SD). Differences between groups were compared using either Student’s t-test or one-way ANOVA asso-
ciated with the Dunnett’s test. Statistical calculation was performed using GraphPad Prism software (GraphPad 
Software Inc., La Jolla, USA) and statistical significance was assumed when p < 0.05. Metabolomic profiling 
results were analyzed by Metabolon Inc. using a Welch’s two-sample-t-test.
References
 1. Fabregat, I. et al. TGF-β signalling and liver disease. FEBS J. 283(12), 2219–2232 (2016).
 2. Giannelli, G. et al. The rationale for targeting TGF-β in chronic liver diseases. Eur J Clin Invest 46(6), 349–361 (2016).
 3. Pavlova, N. & Thomson, C. The emerging hallmarks of cancer metabolism. Cell Metab 23(1), 27–47 (2016).
 4. Liberti, M. & Locasale, J. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 41(3), 211–218 (2016).
 5. Llovet, J., Villanueva, A., Lachenmayer, A. & Finn, R. Advances in targeted therapies for hepatocellular carcinoma in the genomic 
era. Nat Rev Clin Oncol 12(7) (2015).
 6. Beyoğlu, D. & Idle, J. The metabolic window into hepatobiliary disease. J Hepatol 59, 842–858 (2013).
 7. Allain, C., Angenard, G., Clément, B. & Coulouarn, C. Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks 
of Human Hepatocellular Carcinoma. Cancer Res 76(21), 6374–6381 (2016).
 8. Kowalik, M. et al. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. 
Oncotarget 7(22) (2016).
 9. Huang, Q. et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 73(16), 
4992–5002 (2013).
 10. Chafey, P. et al. Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new 
target of the Wnt pathway. Proteomics 9(15), 3889–3900 (2009).
 11. Lachenmayer, A. et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation 
by sorafenib. Clin Cancer Res 18(18), 4997–5007 (2012).
 12. Bertran, E. et al. Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory 
properties to liver tumor cells. Hepatology 58(6), 2032–2044 (2013).
 13. Fernando, J. et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver 
tumor cells. Int J Cancer 136(4), E161–172 (2015).
 14. Malfettone, A. et al. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular 
carcinoma. Cancer Lett 392, 39–50 (2017).
 15. Xie, Q. et al. Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular 
carcinoma cells. Sci Rep 7, 41089 (2017).
 16. Lukey, M., Wilson, K. & Cerione, R. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem 5(14), 
1685–1700 (2013).
 17. Jin, L., Alesi, G. & Kang, S. Glutaminolysis as a target for cancer therapy. Oncogene 35(28), 3619–3625 (2016).
 18. Zhang, C. et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing 
metastasis. Elife 5, e10727 (2016).
 19. Kuo, T. et al. Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells. Cancer Lett 383(2), 
282–294 (2016).
 20. Yu, D. et al. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. 
Oncotarget 6(10), 7619–7631 (2015).
 21. Zielinski, D. et al. System biology analysis of drivers underlying hallmarks of cancer cell metabolism. Sci Rep 7, 41241 (2017).
 22. Nath, A., Li, I., Roberts, L. & Chan, C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in 
hepatocellular carcinoma. Sci Rep 5, 14752 (2015).
 23. Hu, H. et al. Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer 
cells. Am J Physiol Gastrointest Liver Physiol. 307(6), G611–622 (2014).
 24. Valvona, C., Fillmore, H., Nunn, P. & Pilkington, G. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic 
Potential in Brain Tumor. Brain Pathol 26(1), 3–17 (2016).
 25. Miao, P., Sheng, S., Sun, X., Liu, J. & Huang, G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. 
IUBMB Life 65(11), 904–910 (2013).
 26. Sheng, S. et al. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. 
FEBS J. 279(20), 3898–3910 (2012).
 27. Chen, R., Zhou, X., Yu, Z., Liu, J. & Huang, G. Low Expression of LDHB Correlates With Unfavorable Survival in Hepatocellular 
Carcinoma: Strobe-Compliant Article. Medicine (Baltimore) 94(39), e1583 (2015).
 28. Dayton, T., Jacks, T. & Heiden, M. V. PKM2, cancer metabolism, and the road ahead. EMBO Rep. 17(12), 1721–1730 (2016).
 29. Wong, C. et al. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS 
One 9(12), e115036 (2014).
 30. Liu, W. et al. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for 
hepatocellular carcinoma. Oncotarget 6(2), 846–861 (2015).
 31. Álvarez, Z., Hyroššová, P., Perales, J. & Alcántara, S. Neuronal Progenitor Maintenance Requires Lactate Metabolism and PEPCK-
M-Directed Cataplerosis. Cereb Cortex 26(3), 1046–1058 (2016).
Acknowledgements
People Programme (Marie Curie Actions) of the FP7-2013, under REA grant agreement #PITN-GA-2012-316549 
(IT-LIVER) to J.S., A.M., G.G. and I.F. Ministry of Economy and Competitiveness-MINECO, Spain (cofounded 
by FEDER funds/European Regional Development Fund - a way to build Europe): Contract grant numbers: 
SAF2015-64149-R, PIE13/00022 and ISCIII-RTICC RD12-0036-0029 to I.F.; BFU2015-66030-R to J.C.P.; 
SAF2016-75246-R to A.Z.; BFU2014-57466-P to O.Y. AGAUR, Generalitat de Catalunya: Contract grant number 
2014SGR0334 to I.F. I.P.-H. was recipient of a fellowship from the FPI program, Ministry of Economy, Industry 
and Competitiveness, Spain: BES-2016-0077564.
Author Contributions
I.F. conceived and designed the project and obtained funding to develop it. J.S. designed and performed the 
experiments with the help of A.M., I.P.-H. and E.B., which provided some of the cell models used in the study and 
helped in some experiments; P.H. and J.-C.P. contributed to the respiration experiments, lactate production and 
glucose consumption in the HCC cells and actively participated and coordinated with O.Y. the metabolic fluxes 
assays; seahorse analyses were performed with the help of M.-I.H.-A. under the supervision of A.Z.; O.Y. lab 
www.nature.com/scientificreports/
1 5SCIENTIFIC REPORTS | 7: 12486  | DOI:10.1038/s41598-017-12837-y
developed the analysis of metabolic fluxes: A.J. performed metabolites extraction and mass spectrometry analysis 
and data were statistically analyzed by J.C., all under the supervision of O.Y. J.S. and I.F. analyzed the data and 
interpreted the results, with the help of P.H., J.-C.P., M.-I.H.-A., A.Z. and G.G. J.S. and I.F. wrote the manuscript, 
which was revised and modified by J.-C.P. and A.Z. and approved by all the authors.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-12837-y.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
